



## Announcing Olink® Flex, a new, unique and fully flexible low-plex proteomics solution using absolute quantification

November 14, 2022

UPPSALA, Sweden, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for **Olink® Flex**, a fully flexible made-to-order product to select and combine up to 21 human proteins using absolute quantification in one biomarker panel.

With the introduction of Olink® Flex, the Company offers a mix-and-match solution for efficient creation of custom protein biomarker panels with uncompromised data quality, unparalleled specificity, high sensitivity, broad dynamic range, and short turnaround time. Additionally, the solution features absolute quantification methodology for protein concentration measurement, an important feature for many applications spanning clinical to basic research.

Using an online panel builder in [Olink® Insight](#), customers can freely pick and choose 15 to 21 pre-validated assays from over 200 human protein biomarkers covering major biological pathways such as inflammation, immuno-oncology and oncology, neurology, and cardiovascular disease.

With this new product line, Olink enables customers to easily design customized biomarker panels that include the protein assays of their choice, tailored to specific research needs. This latest high-performance solution based on Olink® Proximity Extension Assay (PEA) technology accelerates targeted protein biomarker studies in academic and clinical research to investigate inflammatory processes and immune responses, understand mechanisms of disease and validate unique biomarker signatures.

"I am immensely proud to be able to present this new product to the market. We are continuing to innovate and invest in the expansion of our portfolio to include even more targeted and customizable solutions for protein biomarker research. From a technical perspective this is a very challenging question to solve for; significant multiplex in the low-plex space, customization, absolute quantification, and generating robust and reliable longitudinal data over time such as in a clinical trial. With Olink® Flex, customers now have the opportunity to study specific protein signatures of interest while maintaining the quality, performance, specificity, and sensitivity of our proprietary PEA technology," said **Jon Heimer, CEO of Olink Proteomics**. "Olink® Flex is one of many developments currently underway to serve a broader spectrum of needs within protein biomarker research, providing a wider offering of application-focused mid-plex solutions and more flexible customer offerings."

"We are excited about Olink's Flex panel as it will enable greater flexibility in absolute quantification of our targets of interest for evaluation of new vaccines and antivirals," said **Eugenia Ong, Principal Research Scientist of the Viral Research and Experimental Medicine Centre at SingHealth Duke-NUS Academic Medical Centre (ViREMICS)**.

Olink Flex is fully compatible with **Olink® Signature Q100**, a low maintenance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time and no need for time-consuming washing steps.

With this latest addition, the Olink technology platform now scales from the high-plex product Olink® Explore 3072, to mid-plex Olink® Target 96 and Target 48, down to customized low-plex Olink® Focus and Olink® Flex.

### Olink® Flex Product details

- Online panel builder utilizing the Olink® Insight platform
- Fully flexible made-to-order format to measure 40 samples simultaneously
- Measures up to 21 proteins from only 1µl of sample
- Selection from a broad library of more than 200 highly relevant protein assays
- Readout in pg/mL and Normalized Protein eXpression (NPX)
- Runs on Olink® Signature Q100 and Biomark HD
- NPX Signature software for data quality control and statistical analysis
- Available as reagent kit with turnaround time of 3-5 weeks

For more details, please visit: <https://www.olink.com/products-services/flex/>

### Investor contact

Jan Medina, CFA  
VP Investor Relations & Capital Markets  
[jan.medina@olink.com](mailto:jan.medina@olink.com)

### Media contact

Andrea Prander  
Corporate Communications Manager  
Mobile: +46 768 775 275

[andrea.prander@olink.com](mailto:andrea.prander@olink.com)

#### **About Olink**

[Olink Holding AB](#) (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

#### **Forward-Looking Statements**

This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink's strategy, business plans and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink's business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled "Risk Factors" in Olink's Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.